ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM: Abstract Number: 1964

Penn State Registry of Inflammatory Myopathies (PRIMO) Provides Insights into Disease Features and Co-Morbidity Screening Utilization

(1945–1972) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

9:00AM-11:00AM: Abstract Number: 1803

Perceived Dignity in Patients with Rheumatic Diseases: An Unrecognized Source of Emotional Distress

(1796–1826) Epidemiology & Public Health Poster III

9:00AM-11:00AM: Abstract Number: 2064

Perceptions of Rheumatology Fellows on Mentorship Quality After Implementation of a Formalized Mentorship Program

(2061–2088) Professional Education Poster

9:00AM-11:00AM: Abstract Number: 1872

Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients

(1862–1894) Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1880

Performance of Machine Learning Algorithms in Discriminating Spondyloarthritis Features on Magnetic Resonance Imaging: A Systematic Review and Meta-analysis

(1862–1894) Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2126

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) Score in Relation to Flares in Disease Activity

(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 1867

Peripheral Volumetric Bone Mineral Density and Erosive Disease in Patients with Established Rheumatoid Arthritis: A Cross-Sectional Study Using High-Resolution Peripheral Quantitative Computed Tomography

(1862–1894) Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2240

Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi)

(2227–2256) Spondyloarthritis Including Psoriatic Arthritis – Treatment: SpA Poster III

9:00AM-11:00AM: Abstract Number: 1765

Persistent Cigarette Smoking Is Associated with Rheumatoid Arthritis Onset and Neutrophil Activation in a Prospective Study of At-risk First-Degree Relatives

(1734–1775) RA – Etiology and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 2302

Persistently Active Disease in Adult Patients with Childhood Onset Systemic Lupus Erythematosus

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2144

Pharmacodynamic Effects of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): Results from the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2A IRIS-RA Study

(2141–2176) RA – Treatments Poster III

9:00AM-11:00AM: Abstract Number: 2161

Pharmacokinetic and Safety Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501

(2141–2176) RA – Treatments Poster III

9:00AM-11:00AM: Abstract Number: 2043

Phenotype of Musculoskeletal Manifestations in a Canadian Inception Cohort of Pediatric Patients with Inflammatory Bowel Disease

(2039–2060) Pediatric Rheumatology – Clinical Poster III: Potpourri

9:00AM-11:00AM: Abstract Number: 2112

Physical Activity in a Cohort of Patients with Rheumatoid Arthritis

(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2076

Piloting a Rheumatology and Sports Medicine Case-Based Collaborative Learning Curriculum for Medical Students

(2061–2088) Professional Education Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].